ST Germain D J Co. Inc. Buys 48 Shares of Danaher Co. (NYSE:DHR)

ST Germain D J Co. Inc. raised its holdings in shares of Danaher Co. (NYSE:DHR) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,125 shares of the conglomerate’s stock after purchasing an additional 48 shares during the period. ST Germain D J Co. Inc.’s holdings in Danaher were worth $869,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Tsfg LLC grew its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in shares of Danaher during the second quarter worth $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the first quarter worth $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in Danaher in the 2nd quarter valued at $51,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.9 %

Danaher stock opened at $274.38 on Friday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a market cap of $203.23 billion, a P/E ratio of 46.51, a P/E/G ratio of 4.49 and a beta of 0.83. The company’s 50-day moving average price is $270.72 and its two-hundred day moving average price is $260.02. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.05 EPS. As a group, analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DHR. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Stephens began coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective on the stock. Finally, Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.